PET imaging in oncology

Bar‐Shalom, Rachel; Valdivia, Ana Y.; Blaufox, M. Donald

doi:10.1053/snuc.2000.7439

Cited by 300 publications

(167 citation statements)

References 211 publications

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…6 Accurate preoperative staging, particularly with regard to the depth of tumor invasion, involvement of lymph nodes, and distant metastasis, is vital in determining the most appropriate procedures for curative surgery of thoracic esophageal SCC. 1 In this study, FDG uptake in the primary tumor was detected in 25 of 32 cases, and when the depth of invasion reached the propria muscle layer, FDG uptake was observed in all cases.…”

Section: Discussionmentioning

confidence: 99%

“…However, positron emission tomography (PET), using 18-F-fluorodeoxyglucose (FDG), provides physiologic information that enables the diagnosis of cancer to be based on altered tissue metabolism. 6 In the process of transformation from normal cells, malignant cells develop significant alterations in metabolism. The major changes that occur are increases in DNA synthesis, amino acid use, and glycolysis, 6 and these biochemical changes are the basis for the use of FDG-PET imaging in oncology.…”

mentioning

confidence: 99%

“…6 In the process of transformation from normal cells, malignant cells develop significant alterations in metabolism. The major changes that occur are increases in DNA synthesis, amino acid use, and glycolysis, 6 and these biochemical changes are the basis for the use of FDG-PET imaging in oncology.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma

Kato

Kuwano

Nakajima

et al. 2002

Cancer

277

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma

Kato

Kuwano

Nakajima

et al. 2002

Cancer

277

View full text Add to dashboard Cite

show abstract

“…The value of positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) in the assessment of lymphoma has been investigated. 14,15 PET combines the advantages of nuclear medicine techniques such as Ga-67 scintigraphy as an indicator of tumor viability with improved resolution and a higher sensitivity, thus leading to higher lesion detectability. PET has been used in patients with lymphoma mostly for staging and at the end of treatment, for the differential diagnosis of a residual mass.…”

Section: Discussionmentioning

confidence: 99%

Clinical pretreatment risk factors and Ga‐67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non‐Hodgkin lymphoma

Israel

Mor

Epelbaum

et al. 2002

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUNDClinical pretreatment risk factors indicate the severity of disease in patients with aggressive non‐Hodgkin lymphoma (NHL). Ga‐67 scintigraphy during treatment is an early indicator of treatment‐related features of lymphoma cells. The ability of risk factors and Ga‐67 to predict disease outcome was compared in 139 patients with aggressive NHL.METHODSPretreatment clinical risk factors and Ga‐67 scintigraphy performed after one cycle and at mid‐treatment were evaluated for their correlation with response rate and as predictors of 5‐year failure‐free survival (FFS). Univariate analysis was performed to determine the ability of pretreatment risk factors and Ga‐67 early during treatment to predict FFS. Subsequently, multivariate analysis was performed on the variables with significant univariate results using the Cox proportional hazards method. The predictive value of risk factors and Ga‐67 scintigraphy was calculated to determine their suitability in selecting patients with poor outcome.RESULTSResponse rate correlated with stage of disease (P < 0.01) and the international prognostic index (IPI) score (P < 0.05). Five‐year FFS was predicted by stage of disease (P < 0.004), performance status (P < 0.02), and the IPI score (P < 0.01). Response rate correlated with results of Ga‐67 scintigraphy after one cycle of chemotherapy (P < 0.001) and at mid‐treatment (P < 0.001). Five‐year FFS was predicted by Ga‐67 after one cycle of chemotherapy (P < 0.0004) and at mid‐treatment (P < 0.0001). Positive Ga‐67 after the first cycle of treatment predicted 64% of patients who had failure of treatment. A positive study at mid‐treatment predicted 77% of patients who had treatment failure. Cox analysis showed Ga‐67 after one course (P < 0.0012) and at mid‐treatment (P < 0.0002) as being the most significant variables in predicting FFS.CONCLUSIONSGa‐67 scintigraphy demonstrates early the effect of treatment in patients with aggressive NHL. It is a better predictor than pretreatment risk factors of both response rate and FFS. Positive Ga‐67 early during treatment may be used as an independent test in selecting patients who will not respond favorably to current protocol treatment for early therapeutic modifications. Cancer 2002;94:873–8. © 2002 American Cancer Society.DOI 10.1002/cncr.10344

show abstract

“…The intracellular accumulation of FDG reflects the glycolytic metabolic rate in malignant cells and is useful for imaging cancerous tissues. 28,29 High avidity of FDG has been described for most types of lymphoma. [30][31][32][33][34][35] In our study, FDG-PET presented a higher sensitivity in detecting systemic disease (86%) in comparison to gallium scanning (57%) and CT-scan imaging (72%).…”

Section: Discussionmentioning

confidence: 99%

Imaging features of ocular adnexal lymphoproliferative disease

Sullivan

Valenzuela²

2006

Eye

View full text Add to dashboard Cite

Purpose To evaluate the imaging characteristics of a cohort of patients with ocular adnexal lymphoproliferative disease (OALD). Methods A noncomparative retrospective review between 1992 and 1995 and prospective study from 1995 to 2005 of the clinical, imaging and treatment of 105 patients presenting to tertiary orbital referral centre presenting with OALD. Results One hundred and five patients (mean age 61 years, range 11-90 years) with equal gender distribution were included. Fifty-three were primary and 52 were secondary. Computed tomography (CT) usually showed a well-circumscribed lesion of greater than brain density, moulding to adjacent tissues with moderate enhancement. Aggressive histology was associated with bone destruction, while moulding was associated with indolent histology (Po0.005). MRI in OALD showed intermediate signal intensity on T1-and T2-weighted images and moderate enhancement with gadolinium. Gallium scanning sensitivity to detect ocular adnexal disease was 25 and 57% for systemic involvement. Positron emission tomography (PET) upstaged (71%) of patients with systemic lymphoproliferative involvement, having a higher sensitivity than CT in detecting distant disease (86 vs 72%). Conclusions CT and/or MRI are essential in the evaluation of OALD and can be used to establish that an orbital lesion may be lymphoprolifetaive in nature. Further, these imaging modalities may predict the behaviour of the lymphoma in certain cases. Gallium scanning provides no additional information to CT and does not influence patient treatment. PET represents an important addition to the assessment of OALD with real impact on patient management.

show abstract

PET imaging in oncology

Cited by 300 publications

References 211 publications

Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma

Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma

Clinical pretreatment risk factors and Ga‐67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non‐Hodgkin lymphoma

Imaging features of ocular adnexal lymphoproliferative disease

Contact Info

Product

Resources

About